BioWorld MedTech

March 26, 2013

Deals roundup: Argon to acquire Angiotech interventional unit for $362M

In a move to perhaps eliminate a significant portion of its debt, Angiotech Pharmaceuticals (Vancouver, British Columbia) reported the sale of its interventional products business to Argon Medical Devices (Plano, Texas) for $362.5 million. Read More

Third Rock raises $516M in oversubscribed Fund III

Financings roundup: Bausch + Lomb files IPO registration statement

Washington roundup: FDA warning to Stryker offers no insight into Neptune recall

International report: Stereotaxis receives regulatory approval of Niobe tech in Japan

Agreements/contracts: Aerocrine, Medisoft agree to licensing settlement terms

Court report: BCBSM files motion to dismiss antitrust lawsuit filed against it

Grants roundup: Stanford pediatric cancer study receives funding

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...